Mutant IDH is sufficient to initiate enchondromatosis in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 9, 2015, Pages 2829-2834

  Hirata, Makoto ^a   Sasaki, Masato ^b   Cairns, Rob A ^b   Inoue, Satoshi ^b   Puviindran, Vijitha ^c   Li, Wanda Y ^b   Snow, Bryan E ^a   Jones, Lisa D ^b   Wei, Qingxia ^a   Sato, Shingo ^a   Tang, Yuning J ^a   Nadesan, Puviindran ^c   Rockel, Jason ^a   Whetstone, Heather ^a   Poon, Raymond ^a   Weng, Angela ^a   Gross, Stefan ^d   Straley, Kimberly ^d   Gliser, Camelia ^d   Xu, Yingxia ^e   Wunder, Jay ^f   Mak, Tak W ^b   Alman, Benjamin A ^a,c   more..

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d AGIOS PHARMACEUTICALS   (United States)

^e Chempartner ^*  (China)

^f MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Cartilage tumor; Hedgehog; Isocitrate dehydrogenase

Indexed keywords

2 HYDROXYGLUTARIC ACID; 2 OXOGLUTARIC ACID; COLLAGEN TYPE 2; ISOCITRATE DEHYDROGENASE; TAMOXIFEN; ALPHA-HYDROXYGLUTARATE; GLUTARIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARTILAGE CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENCHONDROMATOSIS; ENZYME ACTIVITY; GENE EXPRESSION; GROWTH PLATE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMATIC MUTATION; AMINO ACID SUBSTITUTION; ANIMAL; BIOSYNTHESIS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; MISSENSE MUTATION; MUTANT MOUSE STRAIN; PATHOLOGY;

ANIMALIA; ERINACEIDAE; MUS;

AMINO ACID SUBSTITUTION; ANIMALS; CHONDROCYTES; COLLAGEN TYPE II; ENCHONDROMATOSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; MICE; MICE, MUTANT STRAINS; MUTATION, MISSENSE;

EID: 84924105507     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1424400112     Document Type: Article

References (39)

1. Hong ED, Carrino JA, Weber KL, Fayad LM (2011) Prevalence of shoulder enchondromas on routine MR imaging. Clin Imaging 35(5): 378-384.
2. Walden MJ, Murphey MD, Vidal JA (2008) Incidental enchondromas of the knee. AJR Am J Roentgenol 190(6): 1611-1615.
3. Bovee JV, Hogendoorn PC, Wunder JS, Alman BA (2010) Cartilage tumours and bone development: Molecular pathology and possible therapeutic targets. Nature Rev Cancer 10(7): 481-488.
4. Levesque J, Bell RS, Marx R, Wunder JS; University of Toronto Division of Orthopaedic Surgery (1996) A Guide to Orthopaedic Tumors (Division of Orthopaedic Surgery, Department of Surgery, University of Toronto, Toronto), p 132.
5. Schwartz HS, et al. (1987) The malignant potential of enchondromatosis. J Bone Joint Surg Am 69(2): 269-274.
6. Silve C, Jüppner H (2006) Ollier disease. Orphanet J Rare Dis 1: 37.
7. Verdegaal SH, et al. (2011) Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: An international multicenter study of 161 patients. Oncologist 16(12): 1771-1779.
8. Hopyan S, et al. (2002) A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet 30(3): 306-310.
9. Tiet TD, et al. (2006) Constitutive hedgehog signaling in chondrosarcoma upregulates tumor cell proliferation. Am J Pathol 168(1): 321-330.
10. Couvineau A, et al. (2008) PTHR1 mutations associated with Ollier disease result in receptor loss of function. Hum Mol Genet 17(18): 2766-2775.
11. Kobayashi T, et al. (2002) PTHrP and Indian hedgehog control differentiation of growth plate chondrocytes at multiple steps. Development 129(12): 2977-2986.
12. Kronenberg HM (2003) Developmental regulation of the growth plate. Nature 423(6937): 332-336.
13. Lanske B, et al. (1996) PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 273(5275): 663-666.
14. Vortkamp A, et al. (1996) Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273(5275): 613-622.
15. Amary MF, et al. (2011) IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224(3): 334-343.
16. Amary MF, et al. (2011) Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 43(12): 1262-1265.
17. Lu C, et al. (2013) Induction of sarcomas by mutant IDH2. Genes Dev 27(18): 1986-1998.
18. Pansuriya TC, et al. (2011) Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 43(12): 1256-1261.
19. Borger DR, et al. (2012) Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 17(1): 72-79.
20. Cairns RA, et al. (2012-1903) IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood 119(8): 1901-1903.
21. Mardis ER, et al. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361(11): 1058-1066.
22. Yan H, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8): 765-773.
23. Figueroa ME, et al. (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6): 553-567.
24. Noushmehr H, et al.; Cancer Genome Atlas Research Network (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17(5): 510-522.
25. Ward PS, et al. (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17(3): 225-234.
26. Sasaki M, et al. (2012) D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev 26(18): 2038-2049.
27. Sasaki M, et al. (2012) IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488(7413): 656-659.
28. Dang L, et al. (2010) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 465(7300): 966.
29. Xu W, et al. (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19(1): 17-30.
30. Pfander D, et al. (2004) Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development. Development 131(10): 2497-2508.
31. Kato Kaneko M, et al. (2014) Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone. Cancer Sci 105(6): 744-748.
32. Liu X, et al. (2013) Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1. Cancer Med 2(6): 803-814.
33. Tarpey PS, et al. (2013) Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nat Genet 45(8): 923-926.
34. Ho L, et al. (2009) Gli2 and p53 cooperate to regulate IGFBP-3-mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. Cancer Cell 16(2): 126-136.
35. Ovchinnikov DA, Deng JM, Ogunrinu G, Behringer RR (2000) Col2a1-directed expression of Cre recombinase in differentiating chondrocytes in transgenic mice. Genesis 26(2): 145-146.
36. Chen M, et al. (2007) Generation of a transgenic mouse model with chondrocytespecific and tamoxifen-inducible expression of Cre recombinase. Genesis 45(1): 44-50.
37. Gosset M, Berenbaum F, Thirion S, Jacques C (2008) Primary culture and phenotyping of murine chondrocytes. Nat Protoc 3(8): 1253-1260.
38. Alman BA, Greel DA, Ruby LK, Goldberg MJ, Wolfe HJ (1996) Regulation of proliferation and platelet-derived growth factor expression in palmar fibromatosis (Dupuytren contracture) by mechanical strain. J Orthop Res 14(5): 722-728.
39. Komori T, et al. (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89(5): 755-764.